Discontinuation One Week Recommendations for GLP-1 Receptor Agonists Prior to Esophagogastroduodenoscopy.

This study aims to evaluate the impact of a one-week discontinuation of long-acting glucagon-like peptide-1 receptor agonists (GLP-1 RAs) prior to Esophagogastroduodenoscopy on gastric preparation quality and the need for repeat esophagogastroduodenoscopy (EGD), in order to determine whether a one-week drug interruption constitutes an appropriate pre-procedural recommendation.

Inclusion Criteria: * • Current use of GLP-1 receptor agonists (GLP-1 RAs) or tirzepatide (defined as discontinuation for no more than one week). * Continuous GLP-1 RA use for at least 4 weeks, or treatment at a near-maximal maintenance dose. * Scheduled to undergo esophagogastroduodenoscopy (EGD) for any indication. * Age between 18 and 70 years. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Provision of written informed consent. * Outpatient status. * If currently receiving medications that stimulate or inhibit gastrointestinal motility, these agents must be discontinued at least 3 days prior to EGD. Exclusion Criteria: * • Severe comorbid conditions precluding safe EGD (e.g., unstable angina, recent myocardial infarction, heart failure, chronic respiratory disease, or bleeding diathesis). * History of prior upper gastrointestinal resection (stomach, intestine, or esophagus). * Any other condition deemed inappropriate by the treating physician. * Body mass index (BMI) \> 40 kg/m². * Liver cirrhosis. * Parkinson's disease. * Dementia. * Use of tricyclic antidepressants or opioid medications for more than 3 months.